Lyme Disease Testing Market Size & Forecasts 2026-2035, By Segments (Sample, End-use, Test, Technology), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Abbott, Quest Diagnostics, LabCorp, Bio-Rad, DiaSorin)

Market Size and Growth Outlook

Lyme Disease Testing Market size is forecast to climb from USD 12.4 billion in 2025 to USD 27.27 billion by 2035, expanding at a CAGR of over 8.2% during 2026-2035. Industry revenue in 2026 is projected at USD 13.29 billion.

• Base Year Value (2025): USD 12.4 Billion
• CAGR (2026-2035): 8.2%
• Forecast Year Value (2035): USD 27.27 Billion
• Historical Data Period: 2021-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Key Takeaways

• North America region held over 49% market share in 2025, impelled by high disease prevalence.
• Asia Pacific region will grow at more than 9.5% CAGR between 2026 and 2035, propelled by emerging healthcare infrastructure.
• The IGRA testing segment in 2025 accounted for 54.45% revenue share, owing to diagnostic accuracy drives IGRA dominance.
• Capturing 57.82% lyme disease testing market share in 2025, hospitals segment expanded its dominance, supported by advanced diagnostic tools in hospitals ensure accurate testing.
• The blood segment reached 61.15% revenue share in 2025, fueled by ease of obtaining blood samples ensures widespread use.
• Leading organizations shaping the lyme disease testing market include Abbott (USA), Quest Diagnostics (USA), LabCorp (USA), Bio-Rad (USA), DiaSorin (Italy), Oxford Immunotec (UK), Euroimmun (Germany), Viramed (Germany), Tecan (Switzerland), Meridian Bioscience (USA).

Market Growth Drivers and Industry Trends

Rising Awareness of Lyme Disease & Tick-borne Illness

The increasing public awareness of Lyme disease and other tick-borne illnesses is significantly impacting the lyme disease testing market. Campaigns by organizations such as the Centers for Disease Control and Prevention (CDC) have heightened consciousness regarding the symptoms and risks associated with Lyme disease, leading to more individuals seeking testing. This heightened awareness is not only influencing consumer behavior but also prompting healthcare providers to prioritize tick-borne diseases in their diagnostic protocols. As a result, companies that offer innovative testing solutions have a strategic opportunity to capture a growing market segment that is increasingly informed and proactive about health issues related to Lyme disease.

Technological Advancements in Diagnostic Testing

Innovations in diagnostic testing technologies are transforming the lyme disease testing market by enhancing accuracy, speed, and accessibility. Developments in molecular diagnostics, such as polymerase chain reaction (PCR) testing, allow for quicker and more reliable detection of Lyme disease, addressing previous limitations of traditional serological methods. Companies like Quest Diagnostics are at the forefront of integrating these advanced technologies into their testing offerings, positioning themselves competitively in a market that values efficiency and precision. This technological shift not only attracts established healthcare providers but also presents entry points for new players focused on developing cutting-edge diagnostic solutions that meet evolving consumer and regulatory expectations.

Expansion in Healthcare Infrastructure & Lab Testing

The ongoing expansion of healthcare infrastructure, particularly in rural and underserved areas, is a crucial driver for the lyme disease testing market. As healthcare facilities enhance their capabilities and increase access to lab testing services, the demand for Lyme disease testing is likely to rise correspondingly. Initiatives led by the World Health Organization (WHO) to improve healthcare access are fostering an environment where more individuals can receive timely diagnoses. This infrastructure growth creates strategic opportunities for both established companies and new entrants to collaborate with healthcare providers, ensuring that testing options are widely available. As healthcare systems continue to evolve, the emphasis on comprehensive testing for tick-borne illnesses will likely remain a priority.

Industry Restraints:

Regulatory Compliance Challenges

The Lyme disease testing market faces significant hurdles due to stringent regulatory compliance requirements imposed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations necessitate exhaustive validation and approval processes for new diagnostic tests, which can lead to operational inefficiencies and extended timelines for product launches. For instance, the FDA's recent guidance on the performance of Lyme disease tests mandates comprehensive clinical data to demonstrate accuracy and reliability, increasing the burden on manufacturers. This complex regulatory landscape not only discourages innovation among new entrants but also pressures established companies to allocate substantial resources toward compliance rather than research and development. As a result, the pace of technological advancement in Lyme disease diagnostics is slowed, limiting the market's potential to respond effectively to evolving consumer needs and public health demands.

Supply Chain Disruptions

Supply chain vulnerabilities are another critical restraint affecting the Lyme disease testing market. The COVID-19 pandemic highlighted the fragility of global supply chains, leading to delays in the procurement of essential materials and components for diagnostic tests. Companies like Abbott Laboratories and Thermo Fisher Scientific have reported challenges in sourcing high-quality reagents and components, which are crucial for accurate Lyme disease testing. These disruptions not only increase operational costs but also create uncertainty in product availability, causing hesitation among healthcare providers and patients regarding test adoption. As supply chain issues persist, particularly in the wake of geopolitical tensions and environmental sustainability pressures, market participants must navigate these complexities to maintain competitive advantage. In the near to medium term, addressing supply chain resilience will be vital for companies aiming to enhance their market position and ensure the timely delivery of reliable Lyme disease testing solutions.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising Awareness of Lyme Disease & Tick-borne Illness	2.50%	Short term (≤ 2 yrs)	North America, Europe (spillover: Asia Pacific)	Medium	Fast
Technological Advancements in Diagnostic Testing	2.70%	Medium term (2–5 yrs)	Europe, Asia Pacific (spillover: North America)	Medium	Moderate
Expansion in Healthcare Infrastructure & Lab Testing	3.00%	Long term (5+ yrs)	North America, Asia Pacific (spillover: Europe)	Medium	Moderate

Regional Demand Dynamics

North America Market Statistics:

North America represented more than 49% of the global lyme disease testing market in 2025, establishing itself as the largest region in this sector. This dominance can be attributed to the high prevalence of Lyme disease, particularly in the United States, where the incidence rates have prompted increased awareness and proactive health measures. Factors such as heightened consumer demand for accurate and timely testing, coupled with advancements in diagnostic technologies, have created a conducive environment for market growth. The Centers for Disease Control and Prevention (CDC) has reported a rise in Lyme disease cases, which further fuels the urgency for effective testing solutions. As a result, North America presents significant opportunities for innovation and investment in the lyme disease testing market, driven by a combination of regulatory support and a growing focus on public health initiatives.

The United States anchors the North American lyme disease testing market, serving as a critical hub for innovation and demand. The high disease prevalence in various states has led to a robust public health response, with organizations such as the CDC actively promoting awareness campaigns and improving testing protocols. This heightened focus on Lyme disease has encouraged companies to develop more accurate and rapid testing solutions, aligning with consumer expectations for reliable healthcare. Moreover, the competitive landscape is marked by strategic collaborations among leading diagnostic firms, such as Quest Diagnostics, which has expanded its testing services to meet the increasing demand. This dynamic environment not only reinforces the U.S.'s pivotal role in the regional market but also highlights the potential for further growth in response to evolving consumer needs and regulatory frameworks. Overall, the U.S. serves as a catalyst for the North American lyme disease testing market, creating pathways for innovation and enhanced healthcare delivery.

Asia Pacific Market Analysis:

Asia Pacific emerged as the fastest-growing region in the lyme disease testing market, registering a robust CAGR of 9.5%. This growth is primarily driven by the emerging healthcare infrastructure across the region, which is significantly enhancing the capacity for disease detection and management. The increasing prevalence of Lyme disease, coupled with rising awareness and improved diagnostic capabilities, has led to a surge in demand for testing services. Moreover, as healthcare systems evolve, investments in advanced diagnostic technologies are becoming more prevalent, allowing for quicker and more accurate results. This trend aligns with broader shifts in consumer preferences toward proactive health management, reflecting a growing emphasis on preventive care and early intervention. Recent initiatives by the World Health Organization and national health agencies underscore the importance of strengthening healthcare frameworks to tackle vector-borne diseases, further supporting the region's market potential. Consequently, Asia Pacific presents substantial opportunities for stakeholders in the lyme disease testing market, driven by both infrastructural advancements and heightened public health priorities.

Japan plays a pivotal role in the Asia Pacific lyme disease testing market, characterized by its advanced healthcare system and strong regulatory framework. The country's emerging healthcare infrastructure is facilitating increased access to innovative diagnostic solutions, which is reshaping consumer demand and purchasing behavior. With a growing focus on preventive healthcare, Japanese consumers are increasingly seeking comprehensive testing options, reflecting a cultural shift toward prioritizing health and wellness. Regulatory initiatives by the Ministry of Health, Labour and Welfare are also fostering an environment conducive to the adoption of advanced testing methodologies, ensuring that healthcare providers can meet the rising demand efficiently. Furthermore, Japan's commitment to technological innovation in healthcare is evident through collaborations between public institutions and private companies, enhancing operational capabilities in disease detection. These factors position Japan as a critical player in the regional market, offering significant opportunities for growth in the lyme disease testing sector.

China is another key player in the Asia Pacific lyme disease testing market, driven by its rapid advancements in healthcare infrastructure and a growing emphasis on public health initiatives. The country's emerging healthcare landscape is marked by increased investments in medical technologies and diagnostic services, which are crucial for addressing the rising incidence of Lyme disease. Consumer preferences are shifting toward more accessible and reliable testing options, spurred by government campaigns aimed at raising awareness about vector-borne diseases. The National Health Commission's efforts to strengthen disease surveillance and response capabilities are further enhancing the market environment, encouraging the adoption of innovative testing solutions. Additionally, China's vast population and diverse geographic landscape necessitate tailored approaches to disease management, creating opportunities for localized testing services. As such, China's evolving healthcare framework not only supports its domestic market but also contributes to the broader growth narrative of the Asia Pacific lyme disease testing market, reinforcing the region's significance in the global landscape.

Europe Market Trends:

Europe has maintained a notable presence in the lyme disease testing market, characterized by moderate growth driven by increasing awareness of tick-borne diseases and advancements in diagnostic technologies. The region's significance is underscored by its robust healthcare infrastructure and a strong emphasis on public health initiatives, which have heightened consumer demand for effective testing solutions. Furthermore, recent regulatory changes by the European Centre for Disease Prevention and Control (ECDC) have reinforced the importance of timely and accurate testing, as rising cases of Lyme disease prompt a shift in healthcare priorities. This dynamic environment, coupled with a growing trend towards digital health solutions, positions Europe as a promising landscape for investment and innovation in the lyme disease testing market.

Germany plays a pivotal role in the European lyme disease testing market, showcasing moderate growth fueled by a strong healthcare system and increasing public awareness campaigns. The Bundeszentrale für gesundheitliche Aufklärung (BZgA) has been instrumental in educating the public about Lyme disease, leading to heightened demand for testing services. Additionally, German companies are at the forefront of developing advanced testing technologies, as seen in recent partnerships between Siemens Healthineers and local biotech firms aimed at enhancing diagnostic accuracy. This synergy between public health initiatives and technological advancements not only bolsters consumer confidence but also positions Germany as a key player in the regional market.

France also contributes significantly to the European lyme disease testing market, with moderate growth driven by heightened regulatory scrutiny and a focus on preventive healthcare. The French Ministry of Health has implemented new guidelines to improve the detection and management of Lyme disease, which has stimulated demand for innovative testing solutions. Companies like bioMérieux have responded by expanding their product lines to include rapid testing kits, aligning with the government’s push for accessible healthcare. This proactive approach enhances France’s competitive edge in the market and underscores the potential for collaboration in addressing public health challenges across Europe.

No card data available for this language/report.

Segment Leadership and Growth Trends

 

Analysis by Technology

The lyme disease testing market for technology is led by IGRA testing, which captured over 54.4% share in 2025. This dominance stems from the diagnostic accuracy that IGRA testing offers, making it a preferred choice among healthcare providers. The increasing demand for reliable and precise testing solutions reflects a broader trend towards enhanced patient care and improved diagnostic methodologies. Organizations like the Centers for Disease Control and Prevention (CDC) have emphasized the importance of accurate testing in managing Lyme disease, further solidifying IGRA's position. For established firms, this segment presents opportunities to innovate and enhance their product offerings, while emerging players can capitalize on the growing demand for advanced diagnostic technologies. As healthcare systems continue to prioritize effective Lyme disease management, IGRA testing is expected to remain a critical component in the near to medium term.

Analysis by End-use

In the lyme disease testing market, hospitals held a commanding 57.8% share in 2025, driven by the integration of advanced diagnostic tools that ensure accurate testing. Hospitals are increasingly adopting sophisticated technologies to meet patient needs, reflecting a shift towards more effective healthcare delivery. The World Health Organization (WHO) has highlighted the role of hospitals in managing infectious diseases, which underscores the significance of reliable testing methods in clinical settings. This segment not only provides established firms with a platform to expand their service capabilities but also offers emerging players a chance to introduce innovative solutions tailored to hospital requirements. With the ongoing investment in hospital infrastructure and technology, the relevance of this segment is expected to persist as healthcare systems evolve.

Analysis by Sample

The lyme disease testing market for sample types is predominantly represented by blood testing, which accounted for more than 61.2% of the market share in 2025. The ease of obtaining blood samples contributes significantly to the widespread use of this testing method among healthcare providers. This preference aligns with patient comfort and operational efficiency, as blood tests can be conducted quickly and with minimal discomfort. Research from the National Institutes of Health (NIH) supports the efficacy of blood testing in diagnosing Lyme disease, reinforcing its status as a reliable method. This segment offers established firms the opportunity to enhance their product lines with improved testing technologies, while new entrants can find niche markets in blood sample innovations. As healthcare professionals increasingly rely on blood testing for timely diagnoses, this segment is poised to maintain its importance in the evolving landscape of Lyme disease management.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Sample	Blood, Urine, CSF, Others
End-use	Hospitals, Diagnostic Laboratories, Others
Test	Serological Test, Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining, Nucleic Acid Test
Technology	IGRA Testing, Others

Competitive Landscape and Market Positioning

Key players in the lyme disease testing market include Abbott, Quest Diagnostics, LabCorp, Bio-Rad, DiaSorin, Oxford Immunotec, Euroimmun, Viramed, Tecan, and Meridian Bioscience. These companies hold significant positions due to their established reputations, extensive product portfolios, and robust distribution networks. Abbott, known for its innovative diagnostic solutions, leverages advanced technologies to enhance testing accuracy. Quest Diagnostics and LabCorp dominate the U.S. market with comprehensive testing services and strong laboratory capabilities, while Bio-Rad and DiaSorin focus on developing specialized assays that cater to niche market needs. European players like Euroimmun and Viramed emphasize high-quality testing kits, contributing to their competitive edge in regional markets. The presence of Tecan and Meridian Bioscience further diversifies the landscape, as they integrate automation and proprietary technologies into their offerings, thus reinforcing their influence in the diagnostic sector.

The competitive environment in the lyme disease testing market is characterized by a dynamic interplay of strategic initiatives among the leading players. Companies are actively engaging in collaborations and partnerships that enhance their technological capabilities and broaden their market reach. For instance, the introduction of new testing methodologies and platforms has been a focal point for several key players, driving innovation and improving diagnostic accuracy. Investments in research and development are prevalent, with companies focusing on refining existing tests and exploring novel biomarkers for better disease detection. This collaborative spirit not only fosters competitive advantages but also accelerates the pace of innovation, ensuring that market leaders remain at the forefront of advancements in lyme disease diagnostics.

Strategic / Actionable Recommendations for Regional Players

In North America, fostering collaborations with healthcare providers and research institutions can significantly enhance testing capabilities and expand market access. Emphasizing partnerships that focus on technology integration may facilitate the development of more comprehensive testing solutions, addressing the evolving needs of clinicians and patients alike.

For participants in the Asia Pacific region, leveraging emerging technologies such as digital health platforms and telemedicine can streamline testing processes and improve patient engagement. Targeting high-growth sub-segments, such as pediatric testing or vector-borne disease panels, may also present lucrative opportunities for market expansion.

In Europe, aligning with regulatory bodies and engaging in public health initiatives can bolster credibility and enhance market positioning. Companies should focus on innovation in testing methodologies to respond effectively to the increasing demand for rapid and accurate diagnostics, ensuring they remain competitive in a rapidly evolving landscape.